Monetisation models in biotech and pharma

Pharma and biotech companies are lagging behind when it comes to squeezing value from their IP assets. Are rights holders missing a trick or are the barriers in this sector much tougher? And are there social costs to this failure?


Unlock unlimited access to all IAM content